Top

Published in:

01-09-2015 | Clinical

Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors

Authors: P. Jiménez-Fonseca, A. Carmona-Bayonas, E. Martín-Pérez, G. Crespo, R. Serrano, M. Llanos, C. Villabona, R. García-Carbonero, J. Aller, J. Capdevila, E. Grande, On behalf of the Spanish Neuroendocrine Tumor Group (GETNE)

Published in: Cancer and Metastasis Reviews | Issue 3/2015

Abstract

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare neoplasms capable of producing hormones. The development of new treatments has improved progression-free survival, albeit with increased toxicity. Health-related quality of life (HRQoL) has become an important endpoint in clinical research to evaluate patients’ well-being in such a contradictory scenario. In this review, we examine key reported outcomes across clinical studies exploring HRQoL in patients with GEP-NETs. We have conducted a review of the literature using PubMed, The Cochrane Library, EMBASE, and Google Scholar. Selection criteria for articles were (1) publication in English between 1995 and 2014, (2) patients with GEP-NET, and (3) analysis of HRQoL, including mental health and psychological symptoms. Forty-nine studies met the inclusion criteria (31 clinical trials, 14 observational studies, and 4 developments of NET-specific HRQoL instruments). The scope and nature of the literature was diverse with 27 instruments used to measure aspects of HRQoL. EORTC QLQ-C30 was the most frequently used, in 38 of the 49 studies. Standardized measures revealed that in spite of generally good HRQoL, GEP-NET patients have specific psychological and physical complaints. The clinical benefit of somatostatin analogs and sunitinib has been clearly supported by HRQoL assessment. Improvement in HRQoL scores or symptom relief over time was also reported in 14 trials of peptide receptor radionuclide therapy, however the absence of randomized studies obviate definitive conclusions. We have also identified several unanswered questions that should be addressed in further research concerning chemotherapy, everolimus, surgery, local ablative therapies, and chemoembolization. Future research should incorporate GEP-NET-specific HRQoL instruments into phase III trials. This review may help both clinicians and researchers to select the most appropriate tools to assess changes in HRQoL in this population.

Yao, J. C., Hassan, M., Phan, A., et al. (2008). One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the united states. Journal of Clinical Oncology, 26(18), 3063–3072.PubMedCrossRef

Beaumont, J. L., Cella, D., Phan, A. T., Choi, S., Liu, Z., & Yao, J. C. (2012). Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population. Pancreas, 41(3), 461–466.PubMedCrossRef

Larsson, G., Sjoden, P. O., Oberg, K., Eriksson, B., & von Essen, L. (2001). Health-related quality of life, anxiety and depression in patients with midgut carcinoid tumours. Acta Oncologica, 40(7), 825–831.PubMedCrossRef

US Department of Health and Human Services. (2006). Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health and Quality of Life Outcomes, 4, 79.CrossRef

Redeker, N. S., Lev, E. L., & Ruggiero, J. (2000). Insomnia, fatigue, anxiety, depression, and quality of life of cancer patients undergoing chemotherapy. Scholarly Inquiry for Nursing Practice, 14(4), 275–290. discussion 291–8.PubMed

Cella, D. (1998). Factors influencing quality of life in cancer patients: anemia and fatigue. Seminars in Oncology, 25(3 Suppl 7), 43–46.PubMed

Coates, A., Gebski, V., Bishop, J. F., et al. (1987). Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. New England Journal of Medicine, 317(24), 1490–1495.PubMedCrossRef

Ganz, P. A., Lee, J. J., & Siau, J. (1991). Quality of life assessment. An independent prognostic variable for survival in lung cancer. Cancer, 67(12), 3131–3135.PubMedCrossRef

Haugland, T., Vatn, M. H., Veenstra, M., Wahl, A. K., & Natvig, G. K. (2009). Health related quality of life in patients with neuroendocrine tumors compared with the general Norwegian population. Quality of Life Research, 18(6), 719–726.PubMedCrossRef

10.

Claringbold, P. G., Brayshaw, P. A., Price, R. A., & Turner, J. H. (2011). Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging, 38(2), 302–311.PubMedCrossRef

11.

Raymond, E., Dahan, L., Raoul, J. L., et al. (2011). Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. New England Journal of Medicine, 364(6), 501–513.PubMedCrossRef

12.

Rinke, A., Muller, H. H., Schade-Brittinger, C., et al. (2009). Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. Journal of Clinical Oncology, 27(28), 4656–4663.PubMedCrossRef

13.

Teunissen, J. J., Kwekkeboom, D. J., & Krenning, E. P. (2004). Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0, Tyr3]octreotate. Journal of Clinical Oncology, 22(13), 2724–2729.PubMedCrossRef

14.

Kalinowski, M., Dressler, M., Konig, A., et al. (2009). Selective internal radiotherapy with Yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: a prospective single center study. Digestion, 79(3), 137–142.PubMedCrossRef

15.

Frilling, A., Weber, F., Saner, F., et al. (2006). Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors. Surgery, 140(6), 967–968.CrossRef

16.

Bushnell, D. L., Jr., O’Dorisio, T. M., O’Dorisio, M. S., et al. (2010). 90Y-edotreotide for metastatic carcinoid refractory to octreotide. Journal of Clinical Oncology, 28(10), 1652–1659.PubMedCrossRef

17.

Zuetenhorst, J. M., Valdes Olmos, R. A., Muller, M., Hoefnagel, C. A., & Taal, B. G. (2004). Interferon and meta-iodobenzylguanidin combinations in the treatment of metastatic carcinoid tumours. Endocrine-Related Cancer, 11(3), 553–561.PubMedCrossRef

18.

Bajetta, E., Procopio, G., Catena, L., et al. (2006). Lanreotide autogel every 6 weeks compared with lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a phase III study. Cancer, 107(10), 2474–2481.PubMedCrossRef

19.

Ruszniewski, P., Ish-Shalom, S., Wymenga, M., et al. (2004). Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology, 80(4), 244–251.PubMedCrossRef

20.

Cwikla, J. B., Sankowski, A., Seklecka, N., et al. (2010). Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study. Annals of Oncology, 21(4), 787–794.PubMedCrossRef

21.

Martin-Richard, M., Massuti, B., Pineda, E., et al. (2013). Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study. BMC Cancer, 13(1), 427.PubMedCentralPubMedCrossRef

22.

O’Toole, D., Ducreux, M., Bommelaer, G., et al. (2000). Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer, 88(4), 770–776.PubMedCrossRef

23.

Kulke, M. H., Lenz, H. J., Meropol, N. J., et al. (2008). Activity of sunitinib in patients with advanced neuroendocrine tumors. Journal of Clinical Oncology, 26(20), 3403–3410.PubMedCrossRef

24.

Kvols, L. K., Oberg, K. E., O’Dorisio, T. M., et al. (2012). Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocrine-Related Cancer, 19(5), 657–666.PubMedCrossRef

25.

Jacobsen, M. B., & Hanssen, L. E. (1995). Clinical effects of octreotide compared to placebo in patients with gastrointestinal neuroendocrine tumours. Report on a double-blind, randomized trial. Journal of Internal Medicine, 237(3), 269–275.PubMedCrossRef

26.

Virgolini, I., Britton, K., Buscombe, J., Moncayo, R., Paganelli, G., & Riva, P. (2002). In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Seminars in Nuclear Medicine, 32(2), 148–155.PubMedCrossRef

27.

Waldherr, C., Pless, M., Maecke, H. R., et al. (2002). Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. Journal of Nuclear Medicine, 43(5), 610–616.PubMed

28.

Forrer, F., Waldherr, C., Maecke, H. R., & Mueller-Brand, J. (2006). Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors. Anticancer Research, 26(1B), 703–707.PubMed

29.

Valkema, R., Pauwels, S., Kvols, L. K., et al. (2006). Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0, Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Seminars in Nuclear Medicine, 36(2), 147–156.PubMedCrossRef

30.

Bushnell, D., O’Dorisio, T., Menda, Y., et al. (2003). Evaluating the clinical effectiveness of 90Y-SMT 487 in patients with neuroendocrine tumors. Journal of Nuclear Medicine, 44(10), 1556–1560.PubMed

31.

Muros, M. A., Varsavsky, M., Iglesias Rozas, P., et al. (2009). Outcome of treating advanced neuroendocrine tumours with radiolabelled somatostatin analogues. Clinical and Translational Oncology, 11(1), 48–53.PubMedCrossRef

32.

Bodei, L., Cremonesi, M., Grana, C. M., et al. (2011). Peptide receptor radionuclide therapy with 177-Lu-DOTATATE: the IEO phase I–II study. European Journal of Nuclear Medicine and Molecular Imaging, 38(12), 2125–2135.PubMedCrossRef

33.

Khan, S., Krenning, E. P., van Essen, M., Kam, B. L., Teunissen, J. J., & Kwekkeboom, D. J. (2011). Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0, Tyr3]octreotate. Journal of Nuclear Medicine, 52(9), 1361–1368.PubMedCrossRef

34.

Arnold, R., Rinke, A., Klose, K. J., et al. (2005). Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clinical Gastroenterology and Hepatology, 3(8), 761–771.PubMedCrossRef

35.

Gyokeres, T., Pulgar, S., Singh, N., Passos, V. Q., & Kelemen, P. (2012). Effect of octreotide LAR on quality of life of 93 Hungarian patients with neuroendocrine tumors. ASCO Meeting Abstract, 30(4_suppl), 362.

36.

Wymenga, A. N., Eriksson, B., Salmela, P. I., et al. (1999). Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. Journal of Clinical Oncology, 17(4), 1111.PubMed

37.

Caplin, M. E., Pavel, M., Cwikła, J. B., et al. (2014). Lanreotide in metastatic enteropancreatic neuroendocrine tumors. New England Journal of Medicine, 371(3), 224–233.PubMedCrossRef

38.

Pavel, M., Unger, N., Borbath, I., et al. (2014). Safety and quality-of-life (QOL) assessments in the open-label, multicenter, phase 3b, expanded access study of everolimus in patients with advanced neuroendocrine tumors (NET). Pancreas, 43(3), 500–501.

39.

Delpassand, E. S., Samarghandi, A., Zamanian, S., et al. (2014). Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience. Pancreas, 43(4), 518–525.PubMedCrossRef

40.

Frojd, C., Larsson, G., Lampic, C., & von Essen, L. (2007). Health related quality of life and psychosocial function among patients with carcinoid tumours. A longitudinal, prospective, and comparative study. Health and Quality of Life Outcomes, 5, 18.PubMedCentralPubMedCrossRef

41.

Larsson, G., von Essen, L., & Sjoden, P. O. (1999). Health-related quality of life in patients with endocrine tumours of the gastrointestinal tract. Acta Oncologica, 38(4), 481–490.PubMedCrossRef

42.

Berglund, G., Liden, A., Hansson, M. G., Oberg, K., Sjoden, P. O., & Nordin, K. (2003). Quality of life in patients with multiple endocrine neoplasia type 1 (MEN 1). Familial Cancer, 2(1), 27–33.PubMedCrossRef

43.

Larsson, G., Haglund, K., & Von Essen, L. (2003). Distress, quality of life and strategies to “keep a good mood” in patients with carcinoid tumours: patient and staff perceptions. European Journal of Cancer Care, 12(1), 46–57.PubMedCrossRef

44.

Von Essen, L., Larsson, G., Oberg, K., & Sjoden, P. O. (2002). “Satisfaction with care”: associations with health-related quality of life and psychosocial function among Swedish patients with endocrine gastrointestinal tumours. European Journal of Cancer Care, 11(2), 91–99.CrossRef

45.

Pezzilli, R., Campana, D., Morselli-Labate, A. M., Fabbri, M. C., Brocchi, E., & Tomassetti, P. (2009). Patient-reported outcomes in subjects with neuroendocrine tumors of the pancreas. World Journal of Gastroenterology, 15(40), 5067–5073.PubMedCentralPubMedCrossRef

46.

Van der Horst-Schrivers, A. N., van Ieperen, E., Wymenga, A. N., et al. (2009). Sexual function in patients with metastatic midgut carcinoid tumours. Neuroendocrinology, 89(2), 231–236.PubMedCrossRef

47.

You, Y. N., Thompson, G. B., Young, W. F., Jr., et al. (2007). Pancreatoduodenal surgery in patients with multiple endocrine neoplasia type 1: operative outcomes, long-term function, and quality of life. Surgery, 142(6), 829–836. discussion 836.e1.PubMedCrossRef

48.

Korse, C. M., Bonfrer, J. M. G., Aaronson, N. K., Hart, A. A. M., & Taal, B. G. (2009). Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine tumors. Neuroendocrinology, 89(3), 296–301.PubMedCrossRef

49.

Davies, A. H., Larsson, G., Ardill, J., et al. (2006). Development of a disease-specific quality of life questionnaire module for patients with gastrointestinal neuroendocrine tumours. European Journal of Cancer, 42(4), 477–484.PubMedCrossRef

50.

Vinik, E., Carlton, C. A., Silva, M. P., & Vinik, A. I. (2009). Development of the Norfolk quality of life tool for assessing patients with neuroendocrine tumors. Pancreas, 38(3), e87–e95.PubMedCrossRef

51.

Yadegarfar, G., Friend, L., Jones, L., et al. (2013). Validation of the EORTC QLQ-GINET21 questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumours. British Journal of Cancer, 108(2), 301–310.PubMedCentralPubMedCrossRef

52.

Vinik, E., Silva, M. P., & Vinik, A. I. (2011). Measuring the relationship of quality of life and health status, including tumor burden, symptoms, and biochemical measures in patients with neuroendocrine tumors. Endocrinology and Metabolism Clinics of North America, 40(1), 97–109.PubMedCrossRef

53.

Vinik, A., Bang, Y., Raoul, J., et al. (2010). Patient-reported outcomes (PROs) in patients (pts) with pancreatic neuroendocrine tumors (NET) receiving sunitinib (SU) in a phase III trial. ASCO Meeting Abstract, 28(15_suppl), 4003.

54.

Haugland, T., Veenstra, M., Vatn, M. H., & Wahl, A. K. (2013). Improvement in stress, general self-efficacy, and health related quality of life following patient education for patients with neuroendocrine tumors: a pilot study. Nursing Research Practice, 2013, 695820.PubMedCentralPubMedCrossRef

55.

Larsson, G., von Essen, L., & Sjoden, P. O. (1998). Quality of life in patients with endocrine tumors of the gastrointestinal tract: patient and staff perceptions. Cancer Nursing, 21(6), 411–420.PubMedCrossRef

56.

Larsson, G., Sjoden, P. O., Oberg, K., & von Essen, L. (1999). Importance-satisfaction discrepancies are associated with health-related quality of life in five-year survivors of endocrine gastrointestinal tumours. Annals of Oncology, 10(11), 1321–1327.PubMedCrossRef

57.

Ramage, J. K., Davies, A. H., & Group EQ of L. (2003). Measurement of quality of life in carcinoid/neuroendocrine tumours. Endocrine-Related Cancer, 10(4), 483–486.PubMedCrossRef

58.

Frojd, C., Lampic, C., Larsson, G., & von Essen, L. (2009). Is satisfaction with doctors’ care related to health-related quality of life, anxiety and depression among patients with carcinoid tumours? A longitudinal report. Scandinavian Journal of Caring Sciences, 23(1), 107–116.PubMedCrossRef

59.

Kulke, M.H., O’Dorisio, T., Yang Qi, M., et al. (2015). Patient-reported symptom experiences following participation in a study of telotristat etiprate for patients with carcinoid tumor and octreotide-refractory diarrhea. Available at: http://www.nanets.net/nanets_cd/2013/pdfs/C13-kulkeabstract2.pdf.Accessed 20 June 2015.

60.

Cheung, Y. B., Goh, C., Thumboo, J., Khoo, K. S., & Wee, J. (2005). Variability and sample size requirements of quality-of-life measures: a randomized study of three major questionnaires. Journal of Clinical Oncology, 23(22), 4936–4944.PubMedCrossRef

61.

Kemmler, G., Holzner, B., Kopp, M., et al. (1999). Comparison of two quality-of-life instruments for cancer patients: the functional assessment of cancer therapy-general and the European Organization for Research and Treatment of Cancer quality of life questionnaire-C30. Journal of Clinical Oncology, 17(9), 2932–2940.PubMed

62.

Aaronson, N. K., Ahmedzai, S., Bergman, B., et al. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365–376.PubMedCrossRef

63.

Fayers, P. M., Aaronson, N. K., Bjordal, K., Groenvold, M., Curran, D., & Bottomley, A. (2001). The EORTC QLQ-C30 scoring manual. Brussels: European Organisation for Research and Treatment of Cancer.

64.

Bredart, A., Bottomley, A., Blazeby, J. M., et al. (2005). An international prospective study of the EORTC cancer in-patient satisfaction with care measure (EORTC IN-PATSAT32). European Journal of Cancer, 41(14), 2120–2131.PubMedCrossRef

65.

Osoba, D., Zee, B., Pater, J., Warr, D., Kaizer, L., & Latreille, J. (1994). Psychometric properties and responsiveness of the EORTC quality of life questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Quality of Life Research, 3(5), 353–364.PubMedCrossRef

66.

Groenvold, M., Klee, M. C., Sprangers, M. A., & Aaronson, N. K. (1997). Validation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient-observer agreement. Journal of Clinical Epidemiology, 50(4), 441–450.PubMedCrossRef

67.

Ringdal, G. I., & Ringdal, K. (1993). Testing the EORTC quality of life questionnaire on cancer patients with heterogeneous diagnoses. Quality of Life Research, 2(2), 129–140.PubMedCrossRef

68.

McLachlan, S. A., Devins, G. M., & Goodwin, P. J. (1999). Factor analysis of the psychosocial items of the EORTC QLQ-C30 in metastatic breast cancer patients participating in a psychosocial intervention study. Quality of Life Research, 8(4), 311–317.PubMedCrossRef

69.

Kaasa, S., Bjordal, K., Aaronson, N., et al. (1995). The EORTC core quality of life questionnaire (QLQ-C30): validity and reliability when analysed with patients treated with palliative radiotherapy. European Journal of Cancer, 31A(13–14), 2260–2263.PubMedCrossRef

70.

Arraras, J. I., Arias, F., Tejedor, M., et al. (2002). The EORTC QLQ-C30 (version 3.0) quality of life questionnaire: validation study for Spain with head and neck cancer patients. Psychooncology, 11(3), 249–256.PubMedCrossRef

71.

Bjordal, K., de Graeff, A., Fayers, P. M., et al. (2000). A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. EORTC Quality of Life Group. European Journal of Cancer, 36(14), 1796–1807.PubMedCrossRef

72.

Whistance, R. N., Conroy, T., Chie, W., et al. (2009). Clinical and psychometric validation of the EORTC QLQ-CR29 questionnaire module to assess health-related quality of life in patients with colorectal cancer. European Journal of Cancer, 45(17), 3017–3026.PubMedCrossRef

73.

Fayers, P., Aaronson, N., Bjordal, K., et al. (2001). The EORTC QLQ-C30 scoring manual (3rd ed.). Brussels: European Organisation for Research and Treatment of Cancer.

74.

Kulke, M. H., Stuart, K., Enzinger, P. C., et al. (2006). Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. Journal of Clinical Oncology, 24(3), 401–406.PubMedCrossRef

75.

Guyatt, G. H., Feeny, D. H., & Patrick, D. L. (1993). Measuring health-related quality of life. Annals of Internal Medicine, 118(8), 622–629.PubMedCrossRef

76.

Smith, K. W., Avis, N. E., & Assmann, S. F. (1999). Distinguishing between quality of life and health status in quality of life research: a meta-analysis. Quality of Life Research, 8(5), 447–459.PubMedCrossRef

77.

Covinsky, K. E., Wu, A. W., Landefeld, C. S., et al. (1999). Health status versus quality of life in older patients: does the distinction matter? American Journal of Medicine, 106(4), 435–440.PubMedCrossRef

78.

Ware, J. E., Jr., & Sherbourne, C. D. (1992). The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care, 30(6), 473–483.PubMedCrossRef

79.

Ware, J., Kosinski, M., & Keller, S. D. (1996). A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Medical Care, 34(3), 220–233.PubMedCrossRef

80.

Cella, D., Beaumont, J. L., Liu, Z., Phan, A. T., Choi, S., & Yao, J. C. (2010). Neuroendocrine tumor disease state and PROMIS health-related quality of life scores. ASCO Meeting Abstract, 28(15_suppl), 6118.

81.

Bucquet, D., Condon, S., & Ritchie, K. (1990). The French version of the Nottingham health profile. A comparison of items weights with those of the source version. Social Science and Medicine, 30(7), 829–835.PubMedCrossRef

82.

Larsson, G., & Janson, E. T. (2008). Anemia in patients with midgut carcinoid, treated with alpha interferon: effects by erythropoietin treatment on the perceived quality of life. European Journal of Cancer Care, 17(2), 200–204.PubMedCrossRef

83.

Webster, K., Cella, D., & Yost, K. (2003). The functional assessment of chronic illness therapy (FACIT) measurement system: properties, applications, and interpretation. Health and Quality of Life Outcomes, 1, 79.PubMedCentralPubMedCrossRef

84.

Yellen, S. B., Cella, D. F., Webster, K., Blendowski, C., & Kaplan, E. (1997). Measuring fatigue and other anemia-related symptoms with the functional assessment of cancer therapy (FACT) measurement system. Journal of Pain and Symptom Management, 13(2), 63–74.PubMedCrossRef

85.

Schell, S. R., Camp, E. R., Caridi, J. G., & Hawkins, I. F., Jr. (2002). Hepatic artery embolization for control of symptoms, octreotide requirements, and tumor progression in metastatic carcinoid tumors. Journal of Gastrointestinal Surgery, 6(5), 664–670.PubMedCrossRef

86.

Boudreaux, J. P., Putty, B., Frey, D. J., et al. (2005). Surgical treatment of advanced-stage carcinoid tumors: lessons learned. Annals of Surgery, 241(6), 839–845.PubMedCentralPubMedCrossRef

87.

Gulec, S. A., Mountcastle, T. S., Frey, D., et al. (2002). Cytoreductive surgery in patients with advanced-stage carcinoid tumors. American Surgeon, 68(8), 667–671.PubMed

88.

Knox, C. D., Feurer, I. D., Wise, P. E., et al. (2004). Survival and functional quality of life after resection for hepatic carcinoid metastasis. Journal of Gastrointestinal Surgery, 8(6), 653–659.PubMedCrossRef

89.

Oken, M. M., Creech, R. H., Tormey, D. C., et al. (1982). Toxicity and response criteria of the Eastern Cooperative Oncology group. American Journal of Clinical Oncology, 5(6), 649–655.PubMedCrossRef

90.

Karnofsky, D. A., & Burchenal, J. H. (1949). The clinical evaluation of chemotherapeutic agents in cancer. New York: Columbia University Press.

91.

Blazeby, J. M., Fayers, P., Conroy, T., et al. (2009). Validation of the European Organization for Research and Treatment of Cancer QLQ-LMC21 questionnaire for assessment of patient-reported outcomes during treatment of colorectal liver metastases. British Journal of Surgery, 96(3), 291–298.PubMedCrossRef

92.

Derogatis, L. R. (1986). The psychosocial adjustment to illness scale (PAIS). Journal of Psychosomatic Research, 30(1), 77–91.PubMedCrossRef

93.

Horowitz, M., Wilner, N., & Alvarez, W. (1979). Impact of event scale: a measure of subjective stress. Psychosomatic Medicine, 41(3), 209–218.PubMedCrossRef

94.

Scheier, M. F., Carver, C. S., & Bridges, M. W. (1994). Distinguishing optimism from neuroticism (and trait anxiety, self-mastery, and self-esteem): a reevaluation of the Life Orientation Test. Journal of Personality and Social Psychology, 67(6), 1063–1078.PubMedCrossRef

95.

Vodermaier, A., Linden, W., & Siu, C. (2009). Screening for emotional distress in cancer patients: a systematic review of assessment instruments. Journal of the National Cancer Institute, 101(21), 1464–1488.PubMedCentralPubMedCrossRef

96.

Hatton, M. Q., & Reed, N. S. (1997). Chemotherapy for neuroendocrine tumors: the Beatson Oncology Centre experience. Clinical Oncology (Royal College of Radiologists), 9(6), 385–389.CrossRef

97.

Khan, M. S., & Caplin, M. E. (2011). Therapeutic management of patients with gastroenteropancreatic neuroendocrine tumours. Endocrine-Related Cancer, 18(Suppl 1), S53–S74.PubMedCrossRef

98.

Sarmiento, J. M., Heywood, G., Rubin, J., Ilstrup, D. M., Nagorney, D. M., & Que, F. G. (2003). Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. Journal of the American College of Surgery, 197(1), 29–37.CrossRef

99.

Touzios, J. G., Kiely, J. M., Pitt, S. C., et al. (2005). Neuroendocrine hepatic metastases: does aggressive management improve survival? Annals of Surgery, 241(5), 775–776.CrossRef

100.

Ahmed, A., Turner, G., King, B., et al. (2009). Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Endocrine-Related Cancer, 16(3), 885–894.PubMedCrossRef

101.

Mayo, S. C., de Jong, M. C., Bloomston, M., et al. (2011). Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis. Annals of Surgical Oncology, 18(13), 3657–3665.PubMedCrossRef

102.

Meranze, S. G., Bream, P. R., & Grzeszczak, E. (2007). Phase II clinical trial of yttrium-90 resin microspheres for the treatment of metastatic neuroendocrine tumor. Presented as a poster at the society of interventional radiology (SIR) 32nd annual scientific meeting 2007; Abs 422. Journal of Vascular and Interventional Radiology, 18(1), S150–S151.CrossRef

103.

Osborne, D. A., Zervos, E. E., Strosberg, J., et al. (2006). Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Annals of Surgical Oncology, 13(4), 572–581.PubMedCrossRef

104.

Hung, J. S., Chang, M. C., Lee, P. H., & Tien, Y. W. (2007). Is surgery indicated for patients with symptomatic nonfunctioning pancreatic neuroendocrine tumor and unresectable hepatic metastases? World Journal of Surgery, 31(12), 2392–2397.PubMedCrossRef

105.

Saxena, A., Chua, T. C., Perera, M., Chu, F., & Morris, D. L. (2012). Surgical resection of hepatic metastases from neuroendocrine neoplasms: a systematic review. Surgical Oncology, 21(3), e131–e141.PubMedCrossRef

106.

Drougas, J. G., Anthony, L. B., Blair, T. K., et al. (1998). Hepatic artery chemoembolization for management of patients with advanced metastatic carcinoid tumors. American Journal of Surgery, 175(5), 408–412.PubMedCrossRef

107.

Loewe, C., Schindl, M., Cejna, M., Niederle, B., Lammer, J., & Thurnher, S. (2003). Permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol: assessment of mid- and long-term results. AJR American Journal of Roentgenology, 180(5), 1379–1384.PubMedCrossRef

108.

Diamandidou, E., Ajani, J. A., Yang, D. J., et al. (1998). Two-phase study of hepatic artery vascular occlusion with microencapsulated cisplatin in patients with liver metastases from neuroendocrine tumors. American Journal of Roentgenology, 170(2), 339–344.PubMedCrossRef

109.

Wessels, F. J., & Schell, S. R. (2001). Radiofrequency ablation treatment of refractory carcinoid hepatic metastases. Journal of Surgical Research, 95(1), 8–12.PubMedCrossRef

110.

Maire, F., Lombard-Bohas, C., O’Toole, D., et al. (2012). Hepatic arterial embolization versus chemoembolization in the treatment of liver metastases from well-differentiated midgut endocrine tumors: a prospective randomized study. Neuroendocrinology, 96(4), 294–300.PubMedCrossRef

111.

Rajekar, H., Bogammana, K., & Stubbs, R. S. (2011). Selective internal radiation therapy for gastrointestinal neuroendocrine tumour liver metastases: a new and effective modality for treatment. International Journal of Hepatology, 2011, 404916.PubMedCentralPubMedCrossRef

112.

Chambers, A. J., Pasieka, J. L., Dixon, E., & Rorstad, O. (2008). The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors. Surgery, 144(4), 643–645.CrossRef

113.

Karnofsky, D. A., Abelmann, W. H., Craver, L. F., & Burchenal, J. H. (1948). The use of the nitrogen mustards in the palliative treatment of carcinoma. With particular reference to bronchogenic carcinoma. Cancer, 1(4), 634–656.CrossRef

114.

Pavel, M., Baudin, E., Couvelard, A., et al. (2012). ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology, 95(2), 157–176.PubMedCrossRef

115.

Yang, T. X., Chua, T. C., & Morris, D. L. (2012). Radioembolization and chemoembolization for unresectable neuroendocrine liver metastases - a systematic review. Surgical Oncology, 21(4), 299–308.PubMedCrossRef

116.

Elias, D., Goere, D., Leroux, G., et al. (2009). Combined liver surgery and RFA for patients with gastroenteropancreatic endocrine tumors presenting with more than 15 metastases to the liver. European Journal of Surgical Oncology, 35(10), 1092–1097.PubMedCrossRef

117.

Huang, Y.-Z., Zhou, S.-C., Zhou, H., & Tong, M. (2013). Radiofrequency ablation versus cryosurgery ablation for hepatocellular carcinoma: a meta-analysis. Hepato-Gastroenterology, 60(125), 1131–1135.PubMed

118.

Akyildiz, H. Y., Mitchell, J., Milas, M., Siperstein, A., & Berber, E. (2010). Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: long-term follow-up. Surgery, 148(6), 1288–1293.PubMedCrossRef

119.

National Cancer Institute (2015). Common terminology criteria for adverse effects (CTCAE) v3.0. Available at: http://ctep.cancer.gov/reporting/ctc.html. Accessed: 20 June 2015.

120.

Krabbe, P. F., Peerenboom, L., Langenhoff, B. S., & Ruers, T. J. (2004). Responsiveness of the generic EQ-5D summary measure compared to the disease-specific EORTC QLQ C-30. Quality of Life Research, 13(7), 1247–1253.PubMedCrossRef

121.

Fayers, P. M., & Sprangers, M. A. (2002). Understanding self-rated health. Lancet, 359(9302), 187–188.PubMedCrossRef

122.

Maton, P. N., Gardner, J. D., & Jensen, R. T. (1989). Use of long-acting somatostatin analog SMS 201-995 in patients with pancreatic islet cell tumors. Digestive Diseases and Sciences, 34(3 Suppl), 28S–39S.PubMedCrossRef

123.

Oberg, K., Kvols, L., Caplin, M., et al. (2004). Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Annals of Oncology, 15(6), 966–973.PubMedCrossRef

124.

Capdevila, J., Sevilla, I., Alonso, V., et al. (2015). Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis. BMC Cancer, 15, 495.

125.

Moertel, C. G., Lefkopoulo, M., Lipsitz, S., Hahn, R. G., & Klaassen, D. (1992). Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. New England Journal of Medicine, 326(8), 519–523.PubMedCrossRef

126.

Moertel, C. G., Kvols, L. K., O’Connell, M. J., & Rubin, J. (1991). Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer, 68(2), 227–232.PubMedCrossRef

127.

Eriksson, B., Skogseid, B., Lundqvist, G., Wide, L., Wilander, E., & Oberg, K. (1990). Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors. Cancer, 65(9), 1883–1890.PubMedCrossRef

128.

Ramanathan, R. K., Cnaan, A., Hahn, R. G., Carbone, P. P., & Haller, D. G. (2001). Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Annals of Oncology, 12(8), 1139–1143.PubMedCrossRef

129.

Strosberg, J. R., Fine, R. L., Choi, J., et al. (2011). First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer, 117(2), 268–275.PubMedPubMedCentralCrossRef

130.

Fine, R. L., Gulati, A. P., Krantz, B. A., et al. (2013). Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: the Pancreas Center at Columbia University experience. Cancer Chemotheraphy and Pharmacology, 71(3), 663–670.CrossRef

131.

Lopez-Lopez, C., Jimenez, P., Crespo, G., et al. (2013). Temozolamide plus capecitabine as salvage treatment for patients with advanced neuroendocrine tumors (NETs) in the community setting. ASCO Meeting Abstract, 31(15_suppl), e15169.

132.

Maire, F., Hammel, P., Faivre, S., et al. (2009). Temozolomide: a safe and effective treatment for malignant digestive endocrine tumors. Neuroendocrinology, 90(1), 67–72.PubMedCrossRef

133.

Ekeblad, S., Sundin, A., Janson, E. T., et al. (2007). Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clinical Cancer Research, 13(10), 2986–2991.PubMedCrossRef

134.

Chan, J. A., Stuart, K., Earle, C. C., et al. (2012). Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. Journal of Clinical Oncology, 30(24), 2963–2968.PubMedCrossRef

135.

Oberg, K., Casanovas, O., Castaño, J. P., et al. (2013). Molecular pathogenesis of neuroendocrine tumors: implications for current and future therapeutic approaches. Clinical Cancer Research, 19(11), 2842–2849.PubMedCrossRef

136.

Benavent, M., de Miguel, M. J., & Garcia-Carbonero, R. (2012). New targeted agents in gastroenteropancreatic neuroendocrine tumors. Targeted Oncology, 7(2), 99–106.PubMedCrossRef

137.

Missiaglia, E., Dalai, I., Barbi, S., et al. (2010). Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. Journal of Clinical Oncology, 28(2), 245–255.PubMedCentralPubMedCrossRef

138.

Pavel, M., Hainsworth, J. D., Baudin, E., Peeters, M., & Hobday, T. J. (2010). A randomized, double-blind, placebo-controlled, multicenter phase III trial of everolimus + octreotide LAR vs placebo + octreotide LAR in patients with neuroendocrine tumors (NET). Annals of Oncology, 21, viii–4.

139.

Yao, J. C., Shah, M. H., Ito, T., et al. (2011). Everolimus for advanced pancreatic neuroendocrine tumors. New England Journal of Medicine, 364(6), 514–523.PubMedCentralPubMedCrossRef

140.

Yao, J. C., Hainsworth, J. D., Wolin, E. M., et al. (2012). Multivariate analysis including biomarkers in the phase III RADIANT-2 study of octreotide LAR plus everolimus (E + O) or placebo (P + O) among patients with advanced neuroendocrine tumors (NET). ASCO Meeting Abstract, 30(4_suppl), 157.

141.

Burris, H. A., 3rd, Lebrun, F., Rugo, H. S., et al. (2013). Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. Cancer, 119(10), 1908–1915.PubMedCrossRef

142.

Motzer, R. J., Escudier, B., Oudard, S., et al. (2008). Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet, 372(9637), 449–456.PubMedCrossRef

143.

Strosberg, J. R., Lincy, J., Winkler, R. E., & Wolin, E. M. (2011). Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): updated results of a randomized, double-blind, placebo-controlled, multicenter, phase III trial (RADIANT-3). ASCO Meeting Abstract, 29(15_suppl), 4009.

144.

Phan, A. T. (2013). Metastatic pancreatic neuroendocrine tumors (pNET): placing current findings into perspective. Cancer Treatment Reviews, 39(1), 3–9.PubMedCrossRef

145.

Raymond, E., Hammel, P., Dreyer, C., et al. (2012). Sunitinib in pancreatic neuroendocrine tumors. Targeted Oncology, 7(2), 117–125.PubMedCrossRef

146.

Oberstein, P. E., & Saif, M. W. (2012). Safety and efficacy of everolimus in adult patients with neuroendocrine tumors. Clinical Medicine Insights Oncology, 6, 41–51.PubMedCentralPubMed

147.

Grande, E., Capdevila, J., Castellano, D., et al. (2015). Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE). Annals of Oncology, pii: mdv252. [Epub ahead of print]

148.

Jiao, Y., Shi, C., Edil, B. H., et al. (2011). DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science, 331(6021), 1199–1203.PubMedCentralPubMedCrossRef

149.

Yao, J. C., Pavel, M., Phan, A. T., et al. (2011). Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. Journal of Clinical Endocrinology and Metabolism, 96(12), 3741–3749.PubMedCrossRef

Title: Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors
Authors: P. Jiménez-Fonseca
A. Carmona-Bayonas
E. Martín-Pérez
G. Crespo
R. Serrano
M. Llanos
C. Villabona
R. García-Carbonero
J. Aller
J. Capdevila
E. Grande
On behalf of the Spanish Neuroendocrine Tumor Group (GETNE)
Publication date: 01-09-2015
Publisher: Springer US
Published in: Cancer and Metastasis Reviews / Issue 3/2015
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-015-9573-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2015

Clinical translation for endometrial cancer stem cells hypothesis

Revisit dietary fiber on colorectal cancer: butyrate and its role on prevention and treatment

New advances in genitourinary cancer: evidence gathered in 2014

Diversity of assessing circulating tumor cells (CTCs) emphasizes need for standardization: a CTC Guide to design and report trials

Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications

The importance of radiotherapy on diffuse large B cell lymphoma treatment: a current review

Keynote webinar | Spotlight on antibody–drug conjugates in cancer